Project Grant R41GM131551

This federal Project Grant award from the National Institutes of Health's Office of Research Infrastructure Programs (CFDA 93.351 - Research Infrastructure Programs) provides $573,919 to The University of Iowa to enhance the open-source distribution and validation of monoclonal antibodies for use in model organism research. The key goals of this 4-year project (Apr 2025 - Mar 2029) are to: 1) develop new open-source methods for producing non-rodent hybridoma monoclonal antibodies, 2) perform...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $205,926 to Abbratech Inc., a small disadvantaged biotechnology business located in Branford, CT. The overarching goal of this "Fast Track" research project is to develop a comprehensive platform for identifying and validating recombinant antibodies that target protein isoform splice-junction sites. This addresses key...

This federal Project Grant award from the National Institutes of Health's Office of Research Infrastructure Programs (CFDA 93.351 - Research Infrastructure Programs) provides $490,145 to the University of Massachusetts to produce and validate monoclonal antibodies that can enhance rigor and reproducibility in research using vertebrate animal models. The award period runs from May 15, 2025 to April 30, 2029. The project aims to develop antibodies targeting proteins in mice, Xenopus, and axolotl...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,815,882 five-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco to expand and transform the Primary Immune Deficiency Treatment Consortium (PIDTC) into an open resource to study therapeutic outcomes and improve health outcomes for patients with inborn errors of immunity. The PIDTC will consolidate tools and infrastructure to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on enhancing the protective capacity of antibodies by improving Fc-mediated immune responses. The $416,276 award to the University of Georgia Research Foundation will investigate factors such as epitope location, antibody glycosylation, and oligomerization that modulate antibody-dependent cell-mediated cytotoxicity...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $867,563 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rockefeller University. The grant aims to develop a pioneering class of broadly neutralizing nanobodies (NB) engineered from llama immune systems to provide comprehensive protection against all betacoronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. The project will strategically expand upon existing NB...

This Project Grant award of $1,000,000 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports the development of advanced antibody discovery workflows by Partillion Bioscience Corp, a for-profit biotechnology company based in Los Angeles, California. The grant aims to significantly enhance Partillion's proprietary "nanovial" technology, which enables ultra high-throughput screening and functional assessment of...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $611,129 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Terasaki Institute for Biomedical Innovation. This 4-year award, spanning from August 2024 to June 2028, aims to develop and validate a multi-organ-on-a-chip (MOC) platform comprised of a vascularized liver-on-a-chip and heart-on-a-chip model. The MOC platform will integrate a microfluidic electrochemical biosensor...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $209,750 to Emory University to leverage antibody-omics to prevent and detect tuberculosis (TB) in children affected by HIV. The overarching goals are to define antibody Fc features associated with protection from Mycobacterium tuberculosis (MTB) infection among HIV-exposed infants (Aim 1) and identify biomarkers...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,262,295.00 to Georgia Tech Research Corp to engineer a hydrogel-based human immune organoid to generate activated human B cells and evaluate their in vivo engraftment. The key objectives are to: 1) bioengineer PEG-4MAL-based lymphoid organoids with human B, T, and stromal cells to recapitulate germinal center B cell...